What we do?

PET Radiopharmaceutical Development and Translation

1. PET imaging biomarker development

    -- endocannabinoid system: fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL), diacylglycerol lipase (DAGL) etc

    -- subtype-specific GPCR targets: metabotropic glutamate receptors (mGlu2), muscarinic acetylcholine receptors, ionotropic glutamate receptors

    -- kinase targets: glycogen synthase kinase 3 (GSK3), anaplastic lymphoma kinase (ALK)

2. PET imaging studies in neurodegenerative disorders, Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Huntington's disease (HD) and dementia with Lewy bodies (DLB)

Precision Radiochemistry

1. Novel radiochemical methods using 11C and 18F

2. Bioconjugation reaction with biological molecules, including aptamer, peptide and protein etc